Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis

Ai, Li; Yuan, Tao; Kong, Deyan; Ni, Zhaohui; Wang, Yongjing; Wang, Zhilun; Wang, Yingxue; Wang, Juandong; Jiang, Yang; Liu, Xiaoli; Zheng, Chengyun

doi:10.3892/etm.2017.4687

Cited by 16 publications

(16 citation statements)

References 50 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study also evaluated the safety of MSC treatment and found no allergic reactions or transfusionrelated SAEs, which was consistent with the findings of previous studies (13,14). Previous studies involving treatment with MSCs for diabetes and ankylosing spondylitis performed by our medical team also revealed favorable safety (22,23). The well-tolerated features of MSCs may be a sound basis for future studies.…”

Section: ' Discussionsupporting

confidence: 89%

Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19

Fang

Kong

et al. 2021

Clinics

Self Cite

View full text Add to dashboard Cite

The coronavirus disease (COVID-19) outbreak has catastrophically threatened public health worldwide and presented great challenges for clinicians. To date, no specific drugs are available against severe acute respiratory syndrome coronavirus 2. Mesenchymal stem cells (MSCs) appear to be a promising cell therapy owing to their potent modulatory effects on reducing and healing inflammation-induced lung and other tissue injuries. The present pilot study aimed to explore the therapeutic potential and safety of MSCs isolated from healthy cord tissues in the treatment of patients with COVID-19. METHODS: Twelve patients with COVID-19 treated with MSCs plus conventional therapy and 13 treated with conventional therapy alone (control) were included. The efficacy of MSC infusion was evaluated by changes in oxygenation index, clinical chemistry and hematology tests, immunoglobulin (Ig) levels, and pulmonary computerized tomography (CT) imaging. The safety of MSC infusion was evaluated based on the occurrence of allergic reactions and serious adverse events. RESULTS:The MSC-treated group demonstrated significantly improved oxygenation index. The area of pulmonary inflammation decreased significantly, and the CT number in the inflammatory area tended to be restored. Decreased IgM levels were also observed after MSC therapy. Laboratory biomarker levels at baseline and after therapy showed no significant changes in either the MSC-treated or control group. CONCLUSION: Intravenous infusion of MSCs in patients with COVID-19 was effective and well tolerated. Further studies involving a large cohort or randomized controlled trials are warranted.

show abstract

Section: ' Discussionsupporting

confidence: 89%

Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19

Fang

Kong

et al. 2021

Clinics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among those around one hundred trials have been conducted for treatment of immune-mediated disorders. These trials started in 2004 [ 23 ] for immune-mediated diseases, such as graft vs. host disease [ 24 ], inflammatory bowel disease [ 25 ], multiple sclerosis [ 26 ], systemic lupus erythematosus [ 27 , 28 ], type I [ 29 , 30 , 31 ] and type II [ 32 ] diabetes, primary Sjögren syndrome [ 33 ], ankylosing spondylitis [ 34 ], and RA [ 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ], among others. Currently the clinical application of MSC-based therapies is being extended to autoimmune hepatitis (NCT01661842 and NCT02997878), chronic autoimmune urticaria (NCT02824393) and refractory autoimmune thrombocytopenia [ 44 ] (NCT04014166) ( Table 1 ).…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications

López‐Santalla

Fernandez-Perez

Garín

2020

Cells

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that affects the lining of the synovial joints leading to stiffness, pain, inflammation, loss of mobility, and erosion of joints. Its pathogenesis is related to aberrant immune responses against the synovium. Dysfunction of innate and adaptive immunity, including dysregulated cytokine networks and immune complex-mediated complement activation, are involved in the progression of RA. At present, drug treatments, including corticosteroids, antirheumatic drugs, and biological agents, are used in order to modulate the altered immune responses. Chronic use of these drugs may cause adverse effects to a significant number of RA patients. Additionally, some RA patients are resistant to these therapies. In recent years, mesenchymal stem/stromal cell (MSCs)-based therapies have been largely proposed as a novel and promising stem cell therapeutic approach in the treatment of RA. MSCs are multipotent progenitor cells that have immunomodulatory properties and can be obtained and expanded easily. Today, nearly one hundred studies in preclinical models of RA have shown promising trends for clinical application. Proof-of-concept clinical studies have demonstrated satisfactory safety profile of MSC therapy in RA patients. The present review discusses MSC-based therapy approaches with a focus on published clinical data, as well as on clinical trials, for treatment of RA that are currently underway.

show abstract

“…UC-MSCs have been reported as promising MSC sources for treating various diseases in humans, including heart failure [74], type 2 diabetes mellitus [75], ankylosing spondylitis [76], and angioplasty for diabetic feet [77].…”

Section: Discussionmentioning

confidence: 99%

Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study

Bich¹,

Thi²,

Chau³

et al. 2020

Stem Cell Res Ther

View full text Add to dashboard Cite

Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. COPD results from chronic inflammation of the lungs. Current treatments, including physical and chemical therapies, provide limited results. Stem cells, particularly mesenchymal stem cells (MSCs), are used to treat COPD. Here, we evaluated the safety and efficacy of umbilical cord-derived (UC)-MSCs for treating COPD. Methods: Twenty patients were enrolled, 9 at stage C and 11 at stage D per the Global Initiative for Obstructive Lung Disease (GOLD) classification. Patients were infused with 10 6 cells/kg of expanded allogeneic UC-MSCs. All patients were followed for 6 months after the first infusion. The treatment end-point included a comprehensive safety evaluation, pulmonary function testing (PFT), and quality-of-life indicators including questionnaires, the 6-min walk test (6MWT), and systemic inflammation assessments. All patients completed the full infusion and 6-month follow-up. Results: No infusion-related toxicities, deaths, or severe adverse events occurred that were deemed related to UC-MSC administration. The UC-MSC-transplanted patients showed a significantly reduced Modified Medical Research Council score, COPD assessment test, and number of exacerbations. However, the forced expiratory volume in 1 s, C-reactive protein, and 6MWT values were nonsignificantly reduced after treatment (1, 3, and 6 months) compared with those before the treatment. Conclusion: Systemic UC-MSC administration appears to be safe in patients with moderate-to-severe COPD, can significantly improve their quality of life, and provides a basis for subsequent cell therapy investigations.

show abstract

Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis

Cited by 16 publications

References 50 publications

Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19

Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19

Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications

Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study

Contact Info

Product

Resources

About